Skye Bioscience, Inc. (NASDAQ:SKYE) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT
Company Participants
Punit Dhillon – President, CEO, Secretary & Director
Conference Call Participants
Frank Tang – Morgan Stanley
Presentation
Frank Tang
Managing Director
Good morning, everyone. My name is Frank Tang, and I’m with the Investment Banking division at Morgan Stanley.
Before we get started, I’d like to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
With that, thank you all for joining us today for the fireside chat with Skye Bioscience. I’m joined today by CEO, Punit Dhillon.
Question-and-Answer Session
Frank Tang
Morgan Stanley
Punit, for those of us who are not as familiar with Skye, can you give us an overview of where Skye sits today, your pipeline and your priorities heading into 2026?
Punit Dhillon
President, CEO, Secretary & Director
Great. Frank, thanks again for the invitation to Morgan Stanley. It’s always a pleasure being at this conference and always very productive.
Yes, we were in Phase II or mid-stage development in obesity and we’re developing a CB1 antibody. That’s a very exciting non-incretin target in terms of the space and the dialogue or discourse has been primarily dominated by the incretin class GLP-1 or GLP-1 combinations. And we are very excited about working on this validated pathway. This is a pathway that’s been well observed to show dominance in terms of weight loss. In fact, there was previous product approved. And the second generation of class of drugs that have been in development, namely our antibody and then also these other peripherally restricted small molecules, have a really distinguished kind of profile where they stay away outside of the brain, and that’s what we’re excited
#Skye #Bioscience #SKYE #Presents #Morgan #Stanley #23rd